Tyler J Neltner, Prakash K Sahoo, Robert W Smith, John Paul V Anders, Jocelyn E Arnett, Richard J Schmidt, Glen O Johnson, Sathish Kumar Natarajan, Terry J Housh
{"title":"补充8周Shilajit对血清1型胶原合成生物标志物Pro-c1α1的影响:一项随机对照试验","authors":"Tyler J Neltner, Prakash K Sahoo, Robert W Smith, John Paul V Anders, Jocelyn E Arnett, Richard J Schmidt, Glen O Johnson, Sathish Kumar Natarajan, Terry J Housh","doi":"10.1080/19390211.2022.2157522","DOIUrl":null,"url":null,"abstract":"<p><p>Type 1 collagen is an abundant structural protein with importance to the skin, eyes, bones, ligaments, tendons, and muscles. Shilajit supplementation has been shown to increase gene expression of collagen synthesis, however, it is unclear if increased gene expression translates to increases in circulating levels. Therefore, the purpose of the present study was to examine the effects of 8 weeks of daily supplementation with 500 mg·d<sup>-1</sup> and 1000 mg·d<sup>-1</sup> of Shilajit versus placebo on serum pro-c1α1, a biomarker of type 1 collagen synthesis. Thirty-five recreationally trained men (mean ± SD: age = 21.1 ± 1.8 yrs; body mass = 80.7 ± 12.4 kg; height = 180.9 ± 6.7 cm) volunteered to participate in this study. Mixed factorial and one-way ANOVAs were used to analyze mean differences between groups, with follow-up t-tests when necessary. Individual subject responses were assessed using the minimal clinically important difference and Chi-squared tests. There were significant (Low dose: <i>p</i> = 0.008, <i>d</i> = 1.2; High dose: <i>p</i> = 0.007, <i>d</i> = 1.3) increases in serum pro-c1α1 from pre- (Low dose: 42.5 ± 12.4 ng·mL<sup>-1</sup>; High dose: 42.7 ± 12.7 ng·mL<sup>-1</sup>) to post-supplementation (Low dose: 82.3 ± 46.5 ng·mL<sup>-1</sup>; High dose: 113.1 ± 78.7 ng·mL<sup>-1</sup>) for the low and high dose groups, however, no change (<i>p</i> > 0.05) for the placebo group. A greater proportion (<i>p</i> = 0.03) of subjects exhibited increases in pro-c1α1 that exceeded the minimal clinically important difference in the high dose Shilajit group (75%) compared to the placebo group (30%), but no differences (<i>p</i> = 0.06) between the low dose Shilajit group (69%) and placebo. In conclusion, 8 weeks of Shilajit supplementation with 500 and 1000 mg·d<sup>-1</sup> increased type 1 collagen synthesis as indicated by serum levels of pro-c1α1.</p>","PeriodicalId":15646,"journal":{"name":"Journal of Dietary Supplements","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effects of 8 Weeks of Shilajit Supplementation on Serum Pro-c1α1, a Biomarker of Type 1 Collagen Synthesis: A Randomized Control Trial.\",\"authors\":\"Tyler J Neltner, Prakash K Sahoo, Robert W Smith, John Paul V Anders, Jocelyn E Arnett, Richard J Schmidt, Glen O Johnson, Sathish Kumar Natarajan, Terry J Housh\",\"doi\":\"10.1080/19390211.2022.2157522\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Type 1 collagen is an abundant structural protein with importance to the skin, eyes, bones, ligaments, tendons, and muscles. Shilajit supplementation has been shown to increase gene expression of collagen synthesis, however, it is unclear if increased gene expression translates to increases in circulating levels. Therefore, the purpose of the present study was to examine the effects of 8 weeks of daily supplementation with 500 mg·d<sup>-1</sup> and 1000 mg·d<sup>-1</sup> of Shilajit versus placebo on serum pro-c1α1, a biomarker of type 1 collagen synthesis. Thirty-five recreationally trained men (mean ± SD: age = 21.1 ± 1.8 yrs; body mass = 80.7 ± 12.4 kg; height = 180.9 ± 6.7 cm) volunteered to participate in this study. Mixed factorial and one-way ANOVAs were used to analyze mean differences between groups, with follow-up t-tests when necessary. Individual subject responses were assessed using the minimal clinically important difference and Chi-squared tests. There were significant (Low dose: <i>p</i> = 0.008, <i>d</i> = 1.2; High dose: <i>p</i> = 0.007, <i>d</i> = 1.3) increases in serum pro-c1α1 from pre- (Low dose: 42.5 ± 12.4 ng·mL<sup>-1</sup>; High dose: 42.7 ± 12.7 ng·mL<sup>-1</sup>) to post-supplementation (Low dose: 82.3 ± 46.5 ng·mL<sup>-1</sup>; High dose: 113.1 ± 78.7 ng·mL<sup>-1</sup>) for the low and high dose groups, however, no change (<i>p</i> > 0.05) for the placebo group. A greater proportion (<i>p</i> = 0.03) of subjects exhibited increases in pro-c1α1 that exceeded the minimal clinically important difference in the high dose Shilajit group (75%) compared to the placebo group (30%), but no differences (<i>p</i> = 0.06) between the low dose Shilajit group (69%) and placebo. In conclusion, 8 weeks of Shilajit supplementation with 500 and 1000 mg·d<sup>-1</sup> increased type 1 collagen synthesis as indicated by serum levels of pro-c1α1.</p>\",\"PeriodicalId\":15646,\"journal\":{\"name\":\"Journal of Dietary Supplements\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Dietary Supplements\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/19390211.2022.2157522\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/12/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"NUTRITION & DIETETICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Dietary Supplements","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/19390211.2022.2157522","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/12/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
Effects of 8 Weeks of Shilajit Supplementation on Serum Pro-c1α1, a Biomarker of Type 1 Collagen Synthesis: A Randomized Control Trial.
Type 1 collagen is an abundant structural protein with importance to the skin, eyes, bones, ligaments, tendons, and muscles. Shilajit supplementation has been shown to increase gene expression of collagen synthesis, however, it is unclear if increased gene expression translates to increases in circulating levels. Therefore, the purpose of the present study was to examine the effects of 8 weeks of daily supplementation with 500 mg·d-1 and 1000 mg·d-1 of Shilajit versus placebo on serum pro-c1α1, a biomarker of type 1 collagen synthesis. Thirty-five recreationally trained men (mean ± SD: age = 21.1 ± 1.8 yrs; body mass = 80.7 ± 12.4 kg; height = 180.9 ± 6.7 cm) volunteered to participate in this study. Mixed factorial and one-way ANOVAs were used to analyze mean differences between groups, with follow-up t-tests when necessary. Individual subject responses were assessed using the minimal clinically important difference and Chi-squared tests. There were significant (Low dose: p = 0.008, d = 1.2; High dose: p = 0.007, d = 1.3) increases in serum pro-c1α1 from pre- (Low dose: 42.5 ± 12.4 ng·mL-1; High dose: 42.7 ± 12.7 ng·mL-1) to post-supplementation (Low dose: 82.3 ± 46.5 ng·mL-1; High dose: 113.1 ± 78.7 ng·mL-1) for the low and high dose groups, however, no change (p > 0.05) for the placebo group. A greater proportion (p = 0.03) of subjects exhibited increases in pro-c1α1 that exceeded the minimal clinically important difference in the high dose Shilajit group (75%) compared to the placebo group (30%), but no differences (p = 0.06) between the low dose Shilajit group (69%) and placebo. In conclusion, 8 weeks of Shilajit supplementation with 500 and 1000 mg·d-1 increased type 1 collagen synthesis as indicated by serum levels of pro-c1α1.
期刊介绍:
The Journal of Dietary Supplements (formerly the Journal of Nutraceuticals, Functional & Medical Foods) has been retitled to reflect the bold departure from a traditional scientific journal presentation to a leading voice for anyone with a stake in dietary supplements. The journal addresses important issues that meet the broad range of interests from researchers, regulators, marketers, educators, and health professionals from academic, governmental, industry, healthcare, public health, and consumer education sectors. This vital tool not only presents scientific information but interprets it - helping you more readily pass it on to your students, patients, clients, or company.